Celanese Corp — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Celanese reported Q3 2026 adjusted EPS of $1.65 (beating guidance), net sales of $2.6B (+6% YoY), and raised full-year adjusted EPS guidance to $6.00–$6.25 from prior range. The company signed a definitive agreement to sell an additional 19% stake in Nutrinova joint venture to Mitsui & Co. for ~$152M cash (closing Q4 2026), retaining 11% interest. Full-year free cash flow outlook increased to $750–$800M; expected net debt-to-EBITDA of ~4.7x by year-end reflects deleveraging progress.
Why this rating
Modest but real strategic wins: Nutrinova sale ($152M ≈ 2.5% of market cap) and raised guidance support narrative. Not transformational, but meaningful for a company executing deleveraging + portfolio optimization.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.